Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Daan W Huntjens; Joost W Vanhommerig; Willem van de Veen; Mirjam Crul

doi:10.1001/jamaoncol.2023.4821

Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

JAMA Oncol. 2024 Jan 1;10(1):131-132. doi: 10.1001/jamaoncol.2023.4821.

Authors

Daan W Huntjens^{1

2}, Joost W Vanhommerig³, Willem van de Veen⁴, Mirjam Crul¹

Affiliations

¹ Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, the Netherlands.
² Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, the Netherlands.
³ Department of Research and Epidemiology, OLVG Hospital, Amsterdam, the Netherlands.
⁴ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.

PMID: 37917074
PMCID: PMC10623296 (available on 2024-11-02)
DOI: 10.1001/jamaoncol.2023.4821

No abstract available

Plain language summary

This cohort study conducted in the Netherlands uses electronic medical records to assess incidence of hypersensitivity reactions with and without H2-receptor antagonist premedication before paclitaxel administration.

MeSH terms

Dexamethasone / therapeutic use
Humans
Infusions, Intravenous
Paclitaxel* / adverse effects
Premedication
Ranitidine* / adverse effects

Substances

Paclitaxel
Ranitidine
Dexamethasone